Biogaia
BioGaia AB, commonly referred to as BioGaia, is a leading biotechnology company headquartered in Sweden. Founded in 1990, the company has established itself as a pioneer in the development of probiotic products, focusing on gut health and overall well-being. With a strong presence in Europe, North America, and Asia, BioGaia operates within the health and wellness industry, specifically in the probiotics sector. The company’s core offerings include a range of probiotic supplements and functional foods, distinguished by their unique strains of Lactobacillus reuteri. BioGaia's commitment to scientific research and innovation has led to numerous key milestones, including partnerships with major global brands and a robust portfolio of clinical studies supporting their products. Recognised for its market leadership, BioGaia continues to enhance its reputation through ongoing advancements in probiotic technology and consumer education.
DitchCarbon Score
How does Biogaia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogaia's score of 59 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biogaia's reported carbon emissions
In 2024, BioGaia reported total greenhouse gas emissions of approximately 7,300,000 kg CO2e, with emissions distributed across various scopes: 73,000 kg CO2e (Scope 1), 33,000 kg CO2e (Scope 2), and 7,168,000 kg CO2e (Scope 3). The previous year, 2023, saw total emissions of about 6,284,000 kg CO2e, comprising 77,000 kg CO2e (Scope 1), 32,000 kg CO2e (Scope 2), and 6,284,000 kg CO2e (Scope 3). BioGaia has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 levels as a baseline. This target has been validated by the Science Based Targets initiative (SBTi) and aligns with the goal of limiting global warming to 1.5°C. The company is also committed to measuring and reducing its Scope 3 emissions, which represent the largest portion of its carbon footprint. Looking ahead, BioGaia has long-term goals to bring its Scope 1 and Scope 2 emissions close to net zero by 2050. These initiatives reflect the company's dedication to sustainability and its proactive approach to addressing climate change, positioning it as a responsible player in the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | - | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 61,000 | 00,000 | 00,000 | 0,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | 2,438,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogaia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
